Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post–PD-1 Immunotherapy
2022 · Cancer Immunology Research · 14 citations
https://doi.org/10.1158/2326-6066.cir-22-0326
M
Mario Presti
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
52
Papers
305
Citations
9
h-index
9
i10-index
Mario Presti is an academic researcher from Copenhagen University Hospital. The author has contributed to research in topics: Immunotherapy and Immune Responses & Cancer Immunotherapy and Biomarkers & Melanoma and MAPK Pathways. The author has an h-index of 9, co-authored 45 publications.
ORCID: 0000-0001-5984-1793Papers by this author
worksSupplementary Material 1 from Uncoupling CD4<sup>+</sup> TIL-mediated tumor killing from JAK-signaling in melanoma
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27031372.v1
Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-mediated tumor killing from JAK-signaling in melanoma
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27031381.v1
Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-mediated tumor killing from JAK-signaling in melanoma
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27031375
Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-mediated tumor killing from JAK-signaling in melanoma
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27031381
Supplementary Material 1 from Uncoupling CD4<sup>+</sup> TIL-mediated tumor killing from JAK-signaling in melanoma
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27031372
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat